Scott & Selber’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.57M Buy
2,225
+1
+0% +$1.18K 0.54% 48
2026
Q2
$2.67M Sell
2,224
-10
-0.4% -$10.2K 0.56% 44
2026
Q1
$2.05M Sell
2,234
-9
-0.4% -$9.12K 0.53% 58
2025
Q4
$2.41M Buy
2,243
+88
+4% +$84.1K 0.6% 51
2025
Q3
$1.64M Buy
2,155
+17
+0.8% +$12.7K 0.42% 68
2025
Q2
$1.67M Buy
2,138
+18
+0.8% +$14K 0.46% 67
2025
Q1
$1.75M Hold
2,120
– – 0.56% 61
2024
Q4
$1.64M Buy
2,120
+1
+0% +$828 0.49% 65
2024
Q3
$1.88M Sell
2,119
-15
-0.7% -$13.5K 0.58% 57
2024
Q2
$1.93M Buy
2,134
+15
+0.7% +$12K 0.62% 55
2024
Q1
$1.65M Sell
2,119
-11
-0.5% -$7.83K 0.56% 63
2023
Q4
$1.24M Sell
2,130
-6
-0.3% -$3.5K 0.47% 66
2023
Q3
$1.15M Sell
2,136
-1
-0% -$515 0.47% 67
2023
Q2
$1M Buy
2,137
+18
+0.8% +$7.55K 0.39% 78
2023
Q1
$728K Buy
2,119
+5
+0.2% +$1.69K 0.31% 90
2022
Q4
$773K Buy
2,114
+29
+1% +$10.3K 0.35% 88
2022
Q3
$674K Buy
+2,085
New +$661K 0.32% 88
2022
Q1
– Sell
-3,200
Closed -$884K – 108
2021
Q4
$884K Buy
+3,200
New +$811K 0.31% 87

Other funds holding LLY

Scott & Selber's LLY Position: Q3 2026 in Review

Scott & Selber increased its Eli Lilly (LLY) stake by 0.04% in Q3 2026, buying an estimated $1.18K and bringing the position to 2,225 shares worth $2.57M. The position accounts for 0.54% of the portfolio, ranked #48.

Scott & Selber first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.67M in Q2 2026. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Scott & Selber held 2,225 shares of Eli Lilly worth $2.57M as of Q3 2026.
  • Scott & Selber bought 1 Eli Lilly share in Q3 2026, an estimated $1.18K.
  • Eli Lilly made up 0.54% of Scott & Selber's portfolio in Q3 2026, its #48 holding.
  • Scott & Selber first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Scott & Selber's Eli Lilly position peaked at $2.67M in Q2 2026.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Scott & Selber's 13F filing for Q3 2026, filed 21 Oct 2026.